The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination

Trial Profile

The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs ACAM 2000; Smallpox vaccine
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 30 Sep 2008 Primary outcome added as reported by ClinicalTrials.gov.
    • 30 Sep 2008 Study completion date has changed from Mar 2003 to Nov 2003 as reported by ClinicalTrials.gov
    • 30 Sep 2008 Planned number of patients changed from 350 to 353 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top